162 mg与81 mg阿司匹林预防子痫前期的比较:一项随机对照试验
这项实用性、随机、开放标签、盲法终点临床试验在高危孕妇中比较每日162 mg与81 mg阿司匹林预防早产子痫前期或伴严重特征子痫前期的效果。365名参与者纳入意向性分析,162 mg组184人、81 mg组181人,主要复合结局发生率分别为14.1%与17.1%(RR 0.83,95%CI 0.51-1.33,P=0.4),两组相似;162 mg组单胎出生体重略低(2.9 kg vs 3.2 kg,P=0.005),胎盘早剥8例 vs 0例(P=0.013)。
要点
- 在高危孕妇中,每日162 mg与81 mg阿司匹林预防早产子痫前期或伴严重特征子痫前期的发生率相似。
- 162 mg组单胎出生体重略低于81 mg组(2.9 kg vs 3.2 kg,P=0.005)。
- 162 mg组胎盘早剥8例,81 mg组0例(P=0.013)。
核心结论
- 在高危孕妇中,于16周妊娠前开始每日服用162 mg或81 mg阿司匹林,早产子痫前期或伴严重特征子痫前期的发生率相似。
研究设计与样本
- 实用性、随机、开放标签、盲法终点临床试验,在高危孕妇中比较每日162 mg与81 mg阿司匹林,从16周妊娠前开始至足月,随访至产后6周。
- 共随机400名参与者,365名有分娩数据并纳入意向性分析,其中162 mg组184名、81 mg组181名。
- 主要复合结局为早产子痫前期(小于37周妊娠)或伴严重特征子痫前期,由对治疗分组设盲的独立研究者裁定。
- 假设81 mg组主要复合结局预期发生率为8.6%,需纳入394名参与者(每组197名)以80%把握度检测162 mg较81 mg降低7.1%,双侧α=0.05。
主要发现
- 主要复合结局发生率:162 mg组26/184(14.1%)vs 81 mg组31/181(17.1%)(相对风险0.83,95%CI 0.51-1.33,P=0.4)。
- 早产子痫前期和足月子痫前期伴严重特征这两个单独结局在阿司匹林组间相似。
- 依从率在各研究访视中162 mg组为88%至91%,81 mg组为89%至92%。
- 单胎出生体重162 mg组略低(2.9 kg vs 3.2 kg,P=0.005)。
- 胎盘早剥在随机分配至162 mg的参与者中发生8例,随机分配至81 mg者中发生0例(P=0.013)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy of 162 mg vs 81 mg aspirin daily for the prevention of preterm preeclampsia (less than 37 weeks of gestation) or preeclampsia with severe features among pregnant people at high risk. METHODS: We conducted a pragmatic, randomized, open-label, blinded endpoint clinical trial. Pregnant people at high risk for preeclampsia were randomized to treatment with either 162 mg or 81 mg aspirin daily beginning before 16 weeks of gestation until term and followed up until 6 weeks postpartum. The primary composite outcome of either preterm preeclampsia or preeclampsia with severe features was adjudicated by independent researchers blinded to treatment group. Secondary outcomes were the components of the composite, adherence to therapy, and maternal and neonatal complications. The anticipated incidence of the primary composite outcome in the 81-mg group was 8.6%. We calculated that enrollment of 394 participants (197 for each group) would have 80% power to detect a 7.1% reduction in the primary outcome with 162 mg aspirin compared with 81 mg, assuming a two-sided α of 0.05. RESULTS: Of 400 participants randomized, 365 had delivery data available and were included in the intention-to-treat analysis, with 184 participants in the 162-mg group and 181 in the 81-mg group. The incidence of preterm preeclampsia or preeclampsia with severe features was 26 of 184 (14.1%) in the 162-mg group compared with 31 of 181 (17.1%) in the 81-mg group (relative risk 0.83, 95% CI, 0.51-1.33, P =.4). Individual outcomes of preterm preeclampsia and term preeclampsia with severe features were similar between aspirin groups. Adherence rates ranged from 88% to 91% and 89% to 92% for the 162-mg group compared with the 81-mg group, respectively, across study visits. Singleton birth weight was slightly lower in the 162-mg group (2.9 kg vs 3.2 kg, P =.005). There were eight cases of placental abruption in participants randomized to 162 mg compared with 0 in those randomized to 81 mg ( P =.013). CONCLUSION: Among people at increased risk for preeclampsia, the rates of preterm preeclampsia or preeclampsia with severe features were similar to rates in those randomized to treatment with either 81 mg or 162 mg aspirin at less than 16 weeks of gestation. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04070573.
引用
- Khander A, Thomas C, Matthews K, et al. Comparison of 162 mg and 81 mg Aspirin for Prevention of Preeclampsia: A Randomized Controlled Trial. Obstet Gynecol. 2025. PMID: 41296512. doi:10.1097/AOG.0000000000006100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。